Q3 2025 CareDx Inc Earnings Call Transcript
Key Points
- CareDx Inc (CDNA) reported a strong third quarter with total revenue of $100.1 million, marking a 21% year-over-year increase.
- The company achieved record revenue in all three business segments: testing services, patient and digital solutions, and lab products.
- CareDx Inc (CDNA) raised its 2025 revenue guidance to $372 million to $376 million, reflecting strong performance.
- The company successfully implemented revenue cycle management improvements, leading to a 200% improvement in total appeals volume and a 60% improvement in claim submission time.
- CareDx Inc (CDNA) launched Histomap Kidney, a breakthrough tissue-based molecular test, showcasing its commitment to innovation in transplant care.
- Transplant volumes across all three solid organs have remained relatively flat year over year, impacting potential growth.
- The company faces potential reimbursement headwinds due to the draft LCD policy for molecular testing for solid organ allograft rejection.
- Despite strong revenue growth, the company noted that kidney transplant volumes have not accelerated as anticipated.
- There is ongoing media scrutiny and criticism regarding transplant practices, which may affect the market dynamics.
- The company is cautious about the impact of payer mix, coverage, and contracts on future revenue per test.
Hello and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I'd like to welcome everyone to the CareDx third quarter 2025 financial results conference call. (Operator Instructions)
I'd now like to turn the conference over to Tina Jacobson, Vice President of Investor relations. Please go ahead.
Thank you, Operator. Good afternoon.
Thank you for joining us today. Earlier today, CareDX released financial results for the third quarter of 2025 ending September 30, 2025. The result is currently available on the company's website at www.CareDx.com. Joining me on today's call are John Hanna, President and Chief Executive Officer, and Nathan Smith, Chief Financial Officer.
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements. Any statements contained in this call that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
